Why You Should Keep an Eye on Vertex Pharmaceuticals Now!
Vertex estimates that over 80 million people in the US are prescribed a medication for acute pain each year.
Analysts estimate the revenue from the acute pain medication to reach $3.7 billion by 2030.
Reading Time: 1 minute
The US Food and Drug Administration (FDA) has approved the non-opioid pain reliever from Vertex Pharmaceuticals for the treatment of acute pain, as announced by the health agency on January 30, 2025. This offers the market, for the first time, an alternative to addictive opioid painkillers. The oral medication branded as Journavx works by influencing a pain signaling pathway that involves sodium channels in the peripheral nervous system and intercepts pain signals before they reach the brain. Opioids, on the other hand, trigger the brain's reward...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
